Matt Larew

Stock Analyst at William Blair

(0.37)
# 4,288
Out of 5,165 analysts
15
Total ratings
30%
Success rate
-23.91%
Average return

Stocks Rated by Matt Larew

Waters
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $290.02
Upside: -
Charles River Laboratories International
Oct 6, 2025
Upgrades: Outperform
Price Target: n/a
Current: $151.97
Upside: -
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $470.00
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.81
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.15
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $6.75
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $129.05
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $48.81
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.61
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $8.73
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $45.01
Upside: -